PMID- 29982779
OWN - NLM
STAT- MEDLINE
DCOM- 20180726
LR  - 20210503
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 57
IP  - suppl_2
DP  - 2018 Feb 1
TI  - Prevention of glucocorticoid morbidity in giant cell arteritis.
PG  - ii11-ii21
LID - 10.1093/rheumatology/kex459 [doi]
AB  - Glucocorticoids are the mainstay of treatment for GCA. Patients often require 
      long-term treatment that may be associated with numerous adverse effects, 
      depending on the dose and the duration of treatment. Trends in recent decades for 
      glucocorticoid use in GCA suggest increasing cumulative doses and longer 
      exposures. Common adverse events (AEs) reported in glucocorticoid-treated GCA 
      patients include osteoporosis, hypercholesterolaemia, hypertension, posterior 
      subcapsular cataract, infections, diabetes mellitus, Cushingoid appearance, 
      adrenal insufficiency and aseptic necrosis of bone. AEs considered most worrisome 
      by patients and rheumatologists include weight gain, psychological effects, 
      osteoporosis, cardiometabolic complications and infections. The challenge is to 
      maximize the benefit-risk ratio by giving the maximum glucocorticoid treatment 
      necessary to control GCA initially and then to prevent relapse but to give the 
      minimum treatment possible to avoid glucocorticoid-related AEs. We discuss the 
      safety issues associated with long-term glucocorticoid use in patients with GCA 
      and strategies for preventing glucocorticoid-related morbidity.
FAU - Buttgereit, Frank
AU  - Buttgereit F
AD  - Department of Rheumatology and Clinical Immunology, Charite-University Medicine 
      Berlin, Berlin, Germany.
FAU - Matteson, Eric L
AU  - Matteson EL
AD  - Division of Rheumatology and Department of Health Sciences Research, Mayo Clinic 
      College of Medicine and Science, Rochester, MN, USA.
FAU - Dejaco, Christian
AU  - Dejaco C
AD  - Department of Rheumatology, Medical University Graz, Graz, Austria.
AD  - Rheumatology Service, South Tyrolian Health Trust, Hospital Bruneck, Bruneck, 
      Italy.
FAU - Dasgupta, Bhaskar
AU  - Dasgupta B
AD  - Department of Rheumatology, Southend University Hospital and Anglia Ruskin 
      University, Essex, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Aged
MH  - Female
MH  - Giant Cell Arteritis/*drug therapy
MH  - Glucocorticoids/administration & dosage/*adverse effects
MH  - Humans
MH  - Long Term Adverse Effects/chemically induced/*prevention & control
MH  - Male
MH  - Risk Assessment
EDAT- 2018/07/10 06:00
MHDA- 2018/07/27 06:00
CRDT- 2018/07/09 06:00
PHST- 2017/06/30 00:00 [received]
PHST- 2018/07/09 06:00 [entrez]
PHST- 2018/07/10 06:00 [pubmed]
PHST- 2018/07/27 06:00 [medline]
AID - 4898140 [pii]
AID - 10.1093/rheumatology/kex459 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii11-ii21. doi: 
      10.1093/rheumatology/kex459.